ReviewDrugs & aging2006
Adverse effects of atypical antipsychotics in the elderly: a review.
Review in Drugs & aging, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI.Drugs in R&D · 2017Pooled it
- Efficacy and tolerability of benzodiazepines for the treatment of behavioral and psychological symptoms of dementia: a systematic review of randomized controlled trials.American journal of Alzheimer's disease and other dementias · 2014Pooled it
- The effects of valbenazine on tardive dyskinesia in older and younger patients.International journal of geriatric psychiatry · 2020Trial
- Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients.British journal of clinical pharmacology · 2008Trial
- Antipsychotic Medication Preferences: A Large-Scale Survey.Pharmacopsychiatry · 2026Article
- Distinguishing features of depression in dementia from primary psychiatric disease.Discover mental health · 2024Review
- Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system.CNS neuroscience & therapeutics · 2023Article
- Brain-Targeted Intranasal Delivery of Zotepine Microemulsion: Pharmacokinetics and Pharmacodynamics.Pharmaceutics · 2022Article
- Comparative Safety Signal Assessment of Hospitalization Associated With the Use of Atypical Antipsychotics.Frontiers in psychiatry · 2022Article
- Histone deacetylase inhibitors mitigate antipsychotic risperidone-induced motor side effects in aged mice and in a mouse model of Alzheimer's disease.Frontiers in psychiatry · 2022Article
- The Art of Safe and Judicious Deprescribing in an Elderly Patient: A Case Report.Geriatrics (Basel, Switzerland) · 2020Article
- Design, Synthesis and Biological Investigation of Flavone Derivatives as Potential Multi-Receptor Atypical Antipsychotics.Molecules (Basel, Switzerland) · 2020Article
- Intranasal Zotepine Nanosuspension: intended for improved brain distribution in rats.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2019Article
- Choosing wisely? Quantifying the extent of three low value psychotropic prescribing practices in Australia.BMC health services research · 2018Article
- Epigenetic Alterations Impact on Antipsychotic Treatment in Elderly Patients.Current treatment options in psychiatry · 2018Article
- Article
- Histone deacetylase inhibitors reverse age-related increases in side effects of haloperidol in mice.Psychopharmacology · 2017Article
- Observational
- Comparative analysis of the treatment of chronic antipsychotic drugs on epileptic susceptibility in genetically epilepsy-prone rats.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2015Article
- Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database.International journal of medical sciences · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Use of antipsychotic medication is very common in the elderly and often an essential therapy. However, successful treatment in the elderly requires appropriate multidimensional assessment of the patient, knowledge of possible multiple co-morbidities, and awareness of the complexities of polypharmacy, age-dependent changes in pharmacokinetics and pharmacodynamics, and drug-drug interactions in this age group. Antipsychotics are known to have a number of adverse effects. New antipsychotics, such as amisulpride, clozapine, olanzapine, risperidone, quetiapine, ziprasidone, zotepine and aripiprazole, may interact with both dopamine and serotonin receptors. However, compared with conventional antipsychotics, they are less likely to cause extrapyramidal symptoms and are better tolerated in the elderly. At the same time, consistent differences between atypical antipsychotics have been demonstrated. Use of clozapine, for example, is limited by the risk of agranulocytosis, whereas this is not a disadvantage of olanzapine, risperidone, quetiapine and, more recently, ziprasidone, which are being widely used with good results in schizophrenia. However, use of the latter agents to treat the behavioural and psychological symptoms of dementia has been restricted because of recent observations of increased cardiovascular events in patients taking risperidone and olanzapine treatment. Nonetheless, careful review of the literature suggests that the available evidence does not support any causal relationship between use of risperidone or olanzapine and cardiovascular events. This article focuses on some of the main adverse effects commonly reported during administration of atypical antipsychotics to elderly patients. Such effects may be partly explained by age-related changes in pharmacokinetics and pharmacodynamics, and partly by the characteristics of the drugs themselves and their different receptor binding profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.